Research Funding

EXTERNAL ACTIVE GRANTS AND CONTRACTS:

1. PI: 1R01CA148706 (NIH/NCI)                         Duane D. Miller (Co-I: 2011-2015; MPI: 2016-2026)          

“Targeting the colchicine site in tubulin for cancer therapy”. Current funding period (2021-2026) total cost: $1.96 million. Total funding awarded for this project $5.7 million.

2. PI:1R01CA240447-01A1 (NIH/NCI)                Muxiang Zhou (MPI)        7/2020-6/2025

“Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer”. Total cost: $2.72 million.

3. PI: 1R01CA193609-01A1 (NIH/NCI)              5/2016-4/2022

“Selective targeting survivin for cancer therapy”. Total cost: $1.96 million.

4. PI: BC190092                    Tiffany Seagroves (Partner PI)                    3/2020-2/2023

DoD Breast Cancer Research Program

Total budget: $2,269,056 for the duration of 3 years

W81XWH2010011: Li’s part of the project  $1,271,866

W81XWH2010019: Seagroves’ part of the project   $997,190

“Discovery of orally bioavailable tubulin inhibitors to overcome taxane resistance in metastatic breast cancer”

5. PI: 1R61NS124923-01 (NIH/NINDS)      Jianxiong Jiang (contact MPI) and Wei Li (MPI)      12/2021-11/2024
“Targeting TRPC3 Channels for Epileptic Seizures”. Total cost: $1.15 million.

6. PI: Oxnard Foundation                   7/2019-6/2022

This foundation grant is to support research in the Li lab to develop new small molecule compounds as potentially more effective treatments for pancreatic cancer. Total cost: $120,000.

7. PI: Sponsored Research Agreement #1      7/2019-6/2022

Private Industry for a cancer drug development. Total cost: $135,000.

8. PI: Sponsored Research Agreement #2      Duane Miller (MPI)            1/2020-1/2022

Private Industry for a cancer drug development. Total cost: $100,000.

9. Co-I: 1R24EY029950-01A1 (NIH/NEI)           Monica Jablonski (PI)      3/2020-2/2025

“Novel Extended Release Glaucoma Therapy for Once Daily Dosing” Total cost: $4.94 million.

10. MPI: R43CA257324-01 (NIH/NCI)          Zhongzhi Wu (NIH contact PI)                     9/2020-8/2022

“Feasibility study of developing SEAK-114 for the treatment of pediatric cancers”. Total cost: $399,964.

Role: MPI, Founder and owner of the awardee company: SEAK Therapeutics LLC.

EXTERNAL PENDING GRANT

11. MPI: R01AG072703-01A1                       Liao (contact PI); Li and Bhaskar (MPIs)    4/2022-3/2027

Validation of a novel tau clearance mechanism”

Percentile score 7%. Anticipate it is within the funding range. Total requested budget: $3.646 million.

ACTIVE INTERNAL FUNDING AND COMPLETED FUNDING:

Please see the relevant sections in the CV.